Archive

Archive for the ‘Orphan Drug Status’ Category

Pluristem’s (PSTI) PLX Cells receive Orphan Drug Status for Treatment of Buerger’s Disease

August 25th, 2011 No comments

The US  FDA designated PSTI’s PLX cells orphan status for the treatment of thromboangiitis obliterans (Buerger’s disease). Read more…

Categories: NASDAQ: PSTI, Orphan Drug Status, Pluristem Therapeutics

Q3/10 Results, BioMimetic Therapeutics (BMTI)

November 4th, 2010 No comments

 BMTI reported a net loss of $7.8M, or $0.29 per diluted share. Read more…

Categories: BioMimetic Therapeutics (BMTI), Orphan Drug Status, Q3/10 Results, Regenerative Medicine

Recombinant Human Platelet’s Orphan Drug Designation, BioMimetic Therapeutics (NASDAQ: BMTI)

August 23rd, 2010 No comments

BMTI has received orphan drug designation from the FDA for its protein therapeutic, recombinant human platelet derived growth factor (rhPDGF-BB), Read more…

Categories: Orphan Drug Status, Regenerative Medicine